カテゴリ： GlobalData, アメリカ, 企業調査

Regen BioPharma Inc (RGBP)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Regen BioPharma Inc (RGBP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8245
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：59
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Regen BioPharma Inc (Regen BioPharma), a subsidiary of Bio-Matrix Scientific Group Inc, is an immunology and immunotherapy space provider. The company concentrates on the development of immunotherapies and cancer stem cell therapies. Its product pipeline includes HemaXellerate, dCellVax, DiffronC, small molecule targeting cancer stem cell genes, telomeres and genomic integrity. Regen BioPharma provides products for aplastic anemia, myelodysplastic syndrome, solid tumors and acute leukemia, breast cancer, hematopoiesis and liver cancer, among others. The company spans its expertise in the development of therapies including small molecules, stem cell treatments and the body’s own immune system. Regen BioPharma is headquartered in La Mesa, California, the US.

Regen BioPharma Inc (RGBP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Regen BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Regen BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Regen BioPharma Acquires Labs Facilities in US 13
Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell 14
Regen BioPharma to Acquire Cancer Stem Cell Intellectual Property from University of Toronto 15
Regen BioPharma Completes Acquisition Of Patented Intellectual Property Of Cancer Gene-Silencing Technology 16
Venture Financing 17
Regen BioPharma Raises US$20 Million In Venture Financing 17
Partnerships 18
Regen BioPharma Enters into Agreement with ChemDiv 18
Regen BioPharma to Enter into Agreement with Eli Lilly 19
Regen BioPharma Enters into Research Agreement with National Institutes of Health 20
Licensing Agreements 21
CheckPoint Immunology Enters into Licensing Agreement with Regen BioPharma 21
Benitec Biopharma Enters Into Licensing Agreement With Regen BioPharma For ddRNAi Gene Silencing Technology 22
Regen BioPharma Enters Licensing Agreement with Pan Am Cancer Treatment Center 24
Equity Offering 25
Regen BioPharma Raises USD0.05 Million in Private Placement of Units 25
Regen BioPharma Raises USD0.05 Million in Private Placement of Units 26
Regen BioPharma Raises Funding in Private Placement of Common Stock 27
Regen BioPharma Raises Funds in Private Placement of Shares 28
Regen BioPharma Raises Funds in Private Placement of Units 29
Regen BioPharma Raises Funding in Private Placement of Series A Preferred Stock 30
Regen BioPharma Raises USD0.15 Million in Private Placement of Units 31
Regen BioPharma Raises USD0.1 Million in Private Placement of Series A Preferred Stock 32
Regen BioPharma Raises funds in Private Placement 33
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 34
Regen BioPharma Raises Funds in Private Placement of Series A Preferred Stock 35
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 36
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 37
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 38
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 39
Debt Offering 40
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 40
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 41
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 42
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 43
Regen BioPharma Inc – Key Competitors 44
Regen BioPharma Inc – Key Employees 45
Regen BioPharma Inc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Corporate Communications 47
Oct 30, 2017: Regen BioPharma Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (BAB) 47
Product News 48
11/08/2017: Regen BioPharma’s Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs 48
Oct 23, 2017: Regen BioPharma Begins Program to Determine the 3-Dimensional Crystal Structure of NR2F6 49
10/16/2017: Regen BioPharma Researchers Capitalize on Key Structure in Compounds that Activate Checkpoint NR2F6 for the Potential Treatment of Autoimmune Diseases 50
10/03/2017: Regen BioPharma Researchers Demonstrate Direct Binding of Proprietary Agonists to Immune Checkpoint NR2F6 51
09/06/2017: Regen BioPharma Researchers Identify Key Structure in Compounds that Activate NR2F6 52
07/25/2017: Regen BioPharma Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators 53
Jul 12, 2017: Regen BioPharma Researchers Discover New Dynamic Compound Which Modulates the NR2F6 Checkpoint 54
May 16, 2017: Regen BioPharma Sees Additional Positive Results on its Medicinal Chemistry Optimization for Modulating NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases 55
Apr 18, 2017: Regen BioPharma Identifies Three New Series of Compounds That Activate NR2F6 56
Apr 12, 2017: Regen BioPharma Sees Success in Its Pre-Clinical Small Molecule Optimization Program for NR2F6 57
Mar 23, 2017: Regen BioPharma Provides Update on NR2F6 Small Molecule Optimization Program for Treating Cancer and Arthritis 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Regen BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Regen BioPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Regen BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Regen BioPharma Acquires Labs Facilities in US 13
Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell 14
Regen BioPharma to Acquire Cancer Stem Cell Intellectual Property from University of Toronto 15
Regen BioPharma Completes Acquisition Of Patented Intellectual Property Of Cancer Gene-Silencing Technology 16
Regen BioPharma Raises US$20 Million In Venture Financing 17
Regen BioPharma Enters into Agreement with ChemDiv 18
Regen BioPharma to Enter into Agreement with Eli Lilly 19
Regen BioPharma Enters into Research Agreement with National Institutes of Health 20
CheckPoint Immunology Enters into Licensing Agreement with Regen BioPharma 21
Benitec Biopharma Enters Into Licensing Agreement With Regen BioPharma For ddRNAi Gene Silencing Technology 22
Regen BioPharma Enters Licensing Agreement with Pan Am Cancer Treatment Center 24
Regen BioPharma Raises USD0.05 Million in Private Placement of Units 25
Regen BioPharma Raises USD0.05 Million in Private Placement of Units 26
Regen BioPharma Raises Funding in Private Placement of Common Stock 27
Regen BioPharma Raises Funds in Private Placement of Shares 28
Regen BioPharma Raises Funds in Private Placement of Units 29
Regen BioPharma Raises Funding in Private Placement of Series A Preferred Stock 30
Regen BioPharma Raises USD0.15 Million in Private Placement of Units 31
Regen BioPharma Raises USD0.1 Million in Private Placement of Series A Preferred Stock 32
Regen BioPharma Raises funds in Private Placement 33
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 34
Regen BioPharma Raises Funds in Private Placement of Series A Preferred Stock 35
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 36
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 37
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 38
Regen BioPharma Raises USD0.1 Million in Private Placement of Shares 39
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 40
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 41
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 42
Regen BioPharma Raises Funds in Public Offering of 10% Notes Due 2020 43
Regen BioPharma Inc, Key Competitors 44
Regen BioPharma Inc, Key Employees 45
Regen BioPharma Inc, Subsidiaries 46

List of Figures
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Regen BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Regen BioPharma Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Regen BioPharma Inc (RGBP)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Cascades Inc：戦略・SWOT・企業財務分析
    Cascades Inc - Strategy, SWOT and Corporate Finance Report Summary Cascades Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Ultra Petroleum Corp (UPL)：石油・ガス：M&Aディール及び事業提携情報
    Summary Ultra Petroleum Corp (Ultra) is an independent upstream company, which develops, produces, operates, explores, and acquires oil and natural gas properties. It develops long-life natural gas reserves in the Green River Basin of Wyoming, the Pinedale and Jonah fields, and oil reserves in the U …
  • PTT Public Co Ltd (PTT)：電力：M&Aディール及び事業提携情報
    Summary PTT Public Co Ltd (PTT) is a state-owned integrated national oil and gas, and petrochemical company. It operates in oil and natural gas, coal, power, and infrastructure businesses. The company carries out oil and natural gas exploration and production; oil refining; procurement, processing, …
  • Cubic Corp (CUB)：企業の財務・戦略的SWOT分析
    Cubic Corp (CUB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Whole Foods Market Inc：戦略・SWOT・企業財務分析
    Whole Foods Market Inc - Strategy, SWOT and Corporate Finance Report Summary Whole Foods Market Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Nippon Chemiphar Co Ltd (4539)：企業の財務・戦略的SWOT分析
    Summary Nippon Chemiphar Co Ltd (Nippon Chemiphar) is a provider of pharmaceutical drugs and health-related services. The company manufactures, supplies, imports and exports ethical pharmaceuticals and diagnostic agents. Nippon Chemiphar offers diagnostic products, such as IgE NC, a diagnostic kit t …
  • Southwest Gas Corporation (SWX)：企業の財務・戦略的SWOT分析
    Southwest Gas Corporation (SWX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Alliqua BioMedical Inc (ALQA)-製薬・医療分野：企業M&A・提携分析
    Summary Alliqua BioMedical Inc (Alliqua BioMedical), formerly HepaLife Technologies Inc is a regenerative technology company that builds a suite of regenerative solutions for wound and tissue repair. The company’s product categories include ultrasound healing therapy, human biologics, antimicrobial …
  • Qantas Airways Limited：企業の戦略・SWOT・財務分析
    Qantas Airways Limited - Strategy, SWOT and Corporate Finance Report Summary Qantas Airways Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Mereo Biopharma Group Plc (MPH)：製薬・医療：M&Aディール及び事業提携情報
    Summary Mereo Biopharma Group Plc (Mereo), formerly Mereo Biopharma Group Ltd is a specialty bio-pharmaceutical company which develops novel medicines for the treatment of rare and specialty diseases. The company’s pipeline products include BPS-804, which is used for the treatment of brittle bone sy …
  • Hill International, Inc. (HIL)：企業の財務・戦略的SWOT分析
    Hill International, Inc. (HIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Baker IDI Heart and Diabetes Institute：製薬・医療：M&Aディール及び事業提携情報
    Summary Baker IDI Heart and Diabetes Institute (Baker Institute) is a medical research organization that offers diagnosis, prevention, treatment of diabetics and cardiovascular disease. The organization offers clinical services such as diabetes services, weight assessment and management clinic healt …
  • Craneware plc (CRW)：企業の財務・戦略的SWOT分析
    Summary Craneware plc (Craneware) is a healthcare technology company that provides revenue integrity solutions. The company provides patient engagement, charge capture and pricing; coding integrity, and revenue recovery and retention products, chargemaster tool kit, online reference tool kit, physic …
  • Par Pacific Holdings Inc (PARR)：石油・ガス：M&Aディール及び事業提携情報
    Summary Par Pacific Holdings Inc (Par Pacific), formerly known as Par Petroleum Corporation, manages, owns and maintains interests in energy and infrastructure related businesses. It has operations across the value chain from natural gas production to distribution and transportation. The company con …
  • Imperial d.d.：企業の戦略・SWOT・財務分析
    Imperial d.d. - Strategy, SWOT and Corporate Finance Report Summary Imperial d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Trex Company Inc (TREX)：企業の財務・戦略的SWOT分析
    Trex Company Inc (TREX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Diamond Offshore Drilling, Inc.：企業の戦略・SWOT・財務情報
    Diamond Offshore Drilling, Inc. - Strategy, SWOT and Corporate Finance Report Summary Diamond Offshore Drilling, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • InfuSystem Holdings Inc (INFU)：企業の財務・戦略的SWOT分析
    Summary InfuSystem Holdings Inc (InfuSystem) is a provider of infusion pumps and related services. The company provides ambulatory infusion pumps and associated clinical services. Its patient services comprise infucare help hotline, infuease, education, and pain management. InfuSystem offers pumps a …
  • Oiltanking GmbH-石油・ガス分野：企業M&A・提携分析
    Summary Oiltanking GmbH (Oiltanking), a subsidiary of Marquard & Bahls AG is an independent tank storage service provider. The company offers storage facilities and associated services for oils, petroleum products, chemicals, biofuels, gases and dry bulk. It owns and operates terminals in Europe, No …
  • JBS S.A.：企業のM&A・事業提携・投資動向
    JBS S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JBS S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆